Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel
Author:
Publisher
Frontiers Media SA
Subject
Pharmacology (medical),Pharmacology
Reference30 articles.
1. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis;Braun;Ann. Rheum. Dis.,2011
2. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries;Brodszky;Eur. J. Health Econ.,2014
3. The cost of Ankylosing Spondylitis in the UK using linked routine and patient-reported survey data;Cooksey;PLoS ONE,2015
4. Governing board and operational board of ECCO. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD);Danese;J. Crohns. Colitis,2013
5. Changes in biosimilar knowledge among European Crohn's Colitis Organization (ECCO) members: an updated survey;Danese;J. Crohns. Colitis.,2016
Cited by 23 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database;Annals of the Rheumatic Diseases;2023-06-16
2. Überblick über Maßnahmen zur Förderung des Einsatzes von Biosimilars in europäischen Ländern;Arzneiverordnungs-Report 2023;2023
3. How do hospital characteristics and ties relate to the uptake of second-generation biosimilars? A longitudinal analysis of Portuguese NHS hospitals, 2015–2021;Expert Review of Pharmacoeconomics & Outcomes Research;2022-11-17
4. The future of drug development for inflammatory bowel disease: the need to ACT (advanced combination treatment);Gut;2022-06-14
5. Évolution des prescriptions de biosimilaires d’étanercept et d’adalimumab en initiation dans la polyarthrite rhumatoïde en France : données du registre ART-SFR;Revue du Rhumatisme;2022-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3